Treatment Options for Relapsing-Remitting Multiple Sclerosis

2017 ◽  
Vol 69 (3) ◽  
pp. 2093-2099
Author(s):  
Yara Mohsen Albalawi ◽  
Sultan Sameer Alhunbusi ◽  
Meshari Sultan Alsudayri
Keyword(s):  
Multiple Sclerosis ◽  
Treatment Options ◽  
Relapsing Remitting ◽  
Remitting Multiple Sclerosis ◽  
Relapsing Remitting Multiple Sclerosis

OP130 Economic Evaluation Of High-Cost Drugs For Relapsing-Remitting Multiple Sclerosis In Thailand

2021 ◽  
Vol 37 (S1) ◽  
pp. 2-3
Author(s):  
Sarayuth Khuntha ◽  
Nuttakarn Budtarad ◽  
Pritaporn Kingkaew ◽  
Phorntida Hadnorntun ◽  
Pattara Leelahavarong
Keyword(s):  
Multiple Sclerosis ◽  
Economic Evaluation ◽  
Usual Care ◽  
Treatment Options ◽  
Cost Effective ◽  
National Database ◽  
Relapsing Remitting ◽  
Lifetime Costs ◽  
Remitting Multiple Sclerosis ◽  
Relapsing Remitting Multiple Sclerosis

IntroductionDrugs for relapsing-remitting multiple sclerosis (RRMS) are costly and not included in the National List of Essential Medicines of Thailand yet. This study aims to conduct an economic evaluation of high-cost drugs for RRMS.MethodsThe Markov model was used to estimate lifetime costs and quality-adjusted life years (QALYs) gained. The treatment options include Interferon beta-1a (IFN) and Teriflunomide (TERI) (first-line), Fingolimod (FIN) and Natalizumab (NATA) (second-line), and Alemtuzumab (ALEM) (third-line) compared with usual care. The effectiveness of drugs was retrieved by network meta-analysis. The probability of health state transition was obtained from primary data. Treatment-related costs were derived from the national database. Other costs and utilities were obtained from the study in Thai RRMS patients.ResultsThe lowest lifetime costs option was usual care (THB2 million) (USD65,808), while the highest QALY gained option was IFN-NATA-ALEM (8.6 QALY gained). All treatment options were not cost-effective compared with usual care at the threshold of THB160,000 (USD5,300) per QALY gained. However, the option of IFN-NATA-ALEM yielded the lowest incremental cost-effectiveness ratio (ICER), which was THB4.4 million (USD144,778) per QALY gained.ConclusionsHigh-cost drugs were not cost-effective; nonetheless, the IFN-NATA-ALEM option could increase QALY gained with the lowest additional budget. The government should negotiate the price of IFN to decrease by eighty percent.

Effects of relapsing-remitting multiple sclerosis on the stomatognathic system: preliminary findings

2020 ◽  
Vol 179 (6) ◽  
Author(s):  
Gabriel Pádua da Silva ◽  
Marcelo Palinkas ◽  
Robson F. Tosta Lopes ◽  
Saulo C. Vallin Fabrin ◽  
Bruno Ferreira ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Stomatognathic System ◽  
Relapsing Remitting ◽  
Remitting Multiple Sclerosis ◽  
Relapsing Remitting Multiple Sclerosis
Sign in / Sign up

Export Citation Format

Share Document